Redeye comments on OncoZenge’s announcement of appointing LINK Medical as CRO for its pivotal phase ...
Smart Eye secures a milestone AIS order from fleet safety provider Optix, marking the first large-sc...
Redeye return with a research update following BioArctic's Q2 and latest newsflow.
In May, Endomines unveiled its updated strategy for 2025–2029.
With additional funds and a streamlined organisation, Sprint Bioscience continues to proactively pro...
This morning, Alligator announced the launch of a new investigator-sponsored phase II/III trial with...
This adds to the initial evaluation announced by Q-linea’s regional partner earlier this year.
This morning, Litium announced the acquisition of Geins, a SaaS e-commerce platform with strong AI a...
Acconeer has announced its A121 pulsed coherent radar has been selected by an additional Japanese ca...
Cell Impact står fortsatt inför stora utmaningar. Q2-rapporten för 2025 visar en omsättning på 2,1 M...
Redeye comments on Alzinova’s announcement that the FDA has approved its IND application for ALZ-101...
Botnia Gold redovisade ett starkt andra kvartal med intäkter på 115 Mkr och ett rörelseresultat på 4...
Redeye initiates coverage of Senzime, a Swedish medtech company specialising in quantitative neuromu...
Redeye comments on Initiator Pharma’s announcement that it has submitted a CTA to the UK authorities...
Flexion is strengthening its position in the alternative app store market, securing four of the ten ...
Taaleri hosted its CMD today in Helsinki. The CMD offered a detailed description of Taaleri's strate...
Enrad AB:s nettoomsättning om 15,2 MSEK under kv2 2025 understeg vår prognos om 16,2 MSEK med ca 6%.
Systemair visar fortsatt organisk tillväxt och förbättrade marginaler under första kvartalet 2026, t...
Alzecures nyemission bereder vägen för en europeisk fas 2a-studie med ACD856 på patienter med tidig ...
Redeye updates its estimates and fair value range following Dala Energi’s Q2 report that was release...
